Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ETON - Eton Pharmaceuticals, Inc.
Market Cap 72.18M P/E - EPS this Y -275.00% Ern Qtrly Grth -
Income -6.69M Forward P/E 31.44 EPS next Y 273.30% 50D Avg Chg -18.00%
Sales 31.38M PEG - EPS past 5Y - 200D Avg Chg -16.00%
Dividend N/A Price/Book 6.42 EPS next 5Y - 52W High Chg -34.00%
Recommedations 2.00 Quick Ratio 1.24 Shares Outstanding 25.84M 52W Low Chg 45.00%
Insider Own 5.39% ROA -12.50% Shares Float 21.76M Beta 1.30
Inst Own 33.13% ROE -44.30% Shares Shorted/Prior 75.49K/69.64K Price 2.83
Gross Margin 59.48% Profit Margin -21.31% Avg. Volume 54,980 Target Price 8.50
Oper. Margin -32.35% Earnings Date Aug 8 Volume 8,456 Change 0.35%
Healthcare | Drug Manufacturers - Specialty & Generic | United States
About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals, Inc. News
12/20/24 Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
12/17/24 Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
12/12/24 Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutions
12/03/24 Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
11/26/24 Eton acquires US rights to neonatal diabetes treatment from AMMTeK
11/26/24 Eton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeK
11/25/24 Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
11/15/24 Eton Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
11/13/24 Q3 2024 Eton Pharmaceuticals Inc Earnings Call
11/13/24 Eton Pharmaceuticals Inc (ETON) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...
11/12/24 Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
11/07/24 Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
11/06/24 Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/29/24 Eton Pharmaceuticals price target raised to $15 from $10 at Craig-Hallum
10/17/24 SWK Holdings Provides Portfolio Update
10/14/24 Analysts Expect Breakeven For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Before Long
10/03/24 Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
09/13/24 Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc.
08/22/24 Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
08/11/24 Eton Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BRYNJELSEN SEAN Chief Executive Offi.. Chief Executive Officer Sep 22 Buy 2.1042 10,000 21,042 1,040,000 09/23/22
Opaleye Management Inc. 10% Owner 10% Owner Aug 06 Sell 5.81 604,500 3,512,145 117,100 08/06/21